329079-68-7

Upstream product

• 371-40-4 4-fluoroaniline 
• 351-04-2 2-chloro-N-(4-fluorophenyl)acetamide 
• 141-43-5 ethanolamine 

Downstream Products

• 697305-48-9 1-(4-fluorophenyl)piperazin-2-one hydrochloride 
• 697305-32-1 (2R,3S)-2-({[4-(4-fluorophenyl)-3-oxopiperazin-1-yl]carbonyl}amino)-3-(1H-indol-3-yl)butanoic acid 
• 697308-64-8 N-[(1R,2S)-1-({[5-[(dimethylamino)methyl]-2-ethoxyphenyl]amino}carbonyl)-2-(1H-indol-3-yl)propyl]-4-(4-fluorophenyl)-3-oxopiperazine-1-carboxamide 

Relevant academic research and scientific papers

Design and synthesis of a novel series of orally active, selective somatostatin receptor 2 agonists for the treatment of type 2 diabetes

The discovery of a novel series of β-methyltryptophan (β MeTrp) derivatives as selective and orally active non-peptide somatostatin receptor 2 (SSTR2) agonists for the treatment of Type 2 diabetes is described. In our previous research, Compound A, β-MeTr

AMINE COMPOUNDS

The present invention provide a compound of the formula:wherein ring A represents an aromatic ring optionally having substituents; B, Y and Ya are the same or different and each represents a bond, etc.; R1 and R2 are the same or different and each represents a hydrogen atom, etc.; R3 represents a hydrogen atom, etc.; R4 and R5 are the same or different and each represents a hydrogen, etc.; R6 represents an indolyl group optionally having substituents; and Z and Za are the same or different and each represents a hydrogen atom, etc.; or a salt thereof or a prodrug thereof, having a somatostatin receptor binding inhibition activity and is useful for preventing and/or treating diseases associated with somatostatin.